Federated Hermes Inc. Sells 29,191 Shares of Becton, Dickinson and Company $BDX

Federated Hermes Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 98.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 583 shares of the medical instruments supplier’s stock after selling 29,191 shares during the quarter. Federated Hermes Inc.’s holdings in Becton, Dickinson and Company were worth $109,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares in the last quarter. Empowered Funds LLC grew its position in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock valued at $1,827,000 after acquiring an additional 1,354 shares during the period. Ameritas Advisory Services LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $40,000. Callan Family Office LLC bought a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $324,000. Finally, IFP Advisors Inc lifted its stake in Becton, Dickinson and Company by 17.8% in the 2nd quarter. IFP Advisors Inc now owns 6,452 shares of the medical instruments supplier’s stock valued at $1,112,000 after purchasing an additional 973 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX beat on the quarter — adjusted EPS $2.91 (above estimates) and revenue $5.25B with margin expansion, showing operating resilience. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD completed the combination of its Biosciences & Diagnostic Solutions business with Waters Corporation — a strategic divestiture that crystallizes a leaner “New BD.” BD Completes Combination with Waters
• Positive Sentiment: Management announced a $4.0B cash deployment plan tied to the Waters transaction (capital return / balance‑sheet actions), which can be supportive for EPS and shareholder value over time. BD Outlines EPS Guidance and $4B Cash Deployment
• Neutral Sentiment: Top‑line growth was modest (reported revenue +1.6% YoY) and the company affirmed revenue growth guidance for the year — positive for stability but not a catalyst for re-rating. Q1 Financial Results
• Neutral Sentiment: Some insiders placed bullish option bets recently (small dollar amount reported), a signal of confidence from insiders but limited scale. Insiders Placed Bullish Bets
• Negative Sentiment: Management set FY‑2026 adjusted EPS guidance for New BD at $12.35–$12.65 — materially below prior consensus (~$14.8), reflecting the sale/spin and lowering the company’s standalone earnings outlook; that guidance reset is the primary negative catalyst. Reuters: Becton Dickinson cuts annual profit forecast
• Negative Sentiment: Market reaction: shares sold off after the print/guidance reset — analysts flagged the guidance shortfall vs. consensus and some maintained cautious ratings (e.g., Hold). Increased volume suggests the guidance-driven repricing is broad-based. Zacks: Stock Dips Despite Earnings Beat

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Piper Sandler upped their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the company a “neutral” rating in a research note on Wednesday, January 28th. Bank of America increased their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research note on Monday, January 5th. Jefferies Financial Group raised their price target on Becton, Dickinson and Company from $215.00 to $220.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Citigroup assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, February 3rd. They issued a “buy” rating and a $233.00 price objective on the stock. Finally, Stifel Nicolaus raised their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Five research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $213.36.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold a total of 2,463 shares of company stock valued at $501,530 over the last three months. 0.40% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Down 1.3%

BDX stock opened at $207.31 on Tuesday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $235.34. The company has a market capitalization of $59.06 billion, a PE ratio of 35.56, a price-to-earnings-growth ratio of 2.32 and a beta of 0.25. The company’s 50-day simple moving average is $200.14 and its 200 day simple moving average is $192.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same quarter in the previous year, the firm posted $3.43 EPS. The business’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a $1.05 dividend. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase program on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.